Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA

ABSTRACT

Introduction: Early diagnosis, monitoring of disease activity, prediction of treatment response, and structural outcome remain major challenges in spondyloarthritis (SpA). Biomarkers could play a role in addressing these challenges, but in SpA there is a lack of suitable biomarkers.

Areas covered: As SpA is clinically and pathophysiologically closely related to psoriasis and inflammatory bowel disease (IBD), we reviewed in literature, the value of serum biomarkers in these conditions with the aim to find potential candidates for assessing SpA.

Expert commentary: Candidates of interest were antimicrobial peptides, including serum human beta defensin-2 (hBD-2) and lipocalin-2 (LCN-2), and class-1 MHC molecule beta2-microglobulin. Since these biomarkers are relevant in psoriasis and/or IBD from a pathophysiological point of view, and may play a role in the pathogenesis of SpA, we recommend further exploration of their value as biomarker in the diagnosis and prognosis of SpA.

KEYWORDS:

• Spondyloarthritis
• psoriasis
• inflammatory bowel diseases
• serum
• biomarkers

Acknowledgments

We would like to thank KL Germar for proof reading the article.

Declaration of interest

R Landewé is a member of the OMERACT biomarker working group. All authors were involved in drafting the article and approved the final version for publication. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

MC Turina was supported by an unrestricted fellowship from Janssen. DL Baeten was supported by a VICI grant from The Netherlands Organization for Scientific Research (NWO), by a grant from the Dutch Arthritis Foundation (Reumafonds), and by a grant of the European Research Council (ERC).